Dysregulation of p97/VCP disease mutants in IBM and FTLD-U

IBM 和 FTLD-U 中 p97/VCP 疾病突变体的失调

• 批准号: 9889186
• 负责人: Tsui-Fen Chou
• 金额: $ 51.85万
• 依托单位: CALIFORNIA INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9889186
• 关键词: ALS patients; ATP phosphohydrolase; Affect; Affinity; Alleles; Amino Acids; Amyotrophic Lateral Sclerosis; Animal Model; Apoptosis; Area; Autophagocytosis; Binding; Biochemical; Bioinformatics; Biological Assay; Biological Process; Brain; Cell Death; Cells; Clinical; Data; Defect; Degenerative Disorder; Development; Disease; Disease Marker; Emery-Dreifuss Muscular Dystrophy; Enzymes; Excision; Exhibits; Fibroblasts; Frontotemporal Dementia; Genetic; Genotype; Goals; Golgi Apparatus; Hela Cells; Heterogeneous-Nuclear Ribonucleoproteins; Human; Impairment; Inclusion Bodies; Inclusion Body Myopathy with Early-Onset Paget Disease; Inherited; Integral Membrane Protein; Knock-in Mouse; Knock-out; Lead; Leadership; LoxP-flanked allele; Measures; Mediating; Methodology; Missense Mutation; Mitotic; Modeling; Molecular; Molecular Conformation; Motor Neuron Disease; Motor Neurons; Muscle Cells; Mutate; Mutation; Myopathy; Neurodegenerative Disorders; Neurons; Osteitis Deformans; Pathogenicity; Pathology; Pathway interactions; Patients; Penetrance; Phenotype; Precision therapeutics; Protein Family; Proteins; Proteomics; Public Health; Publishing; Quality Control; Recycling; Regulation; Reporter; Source; Symptoms; System; Testing; Therapeutic Intervention; Ubiquitin; Work; age related; base; caveolin 1; cofactor; design; disease phenotype; experience; experimental study; improved; induced pluripotent stem cell; inhibitor/antagonist; knock-down; macromolecule; mouse model; multicatalytic endopeptidase complex; mutant; nervous system disorder; new therapeutic target; novel therapeutics; overexpression; p97 ATPase; prevent; protein TDP-43; protein misfolding; skills; small molecule inhibitor; stem cells; targeted treatment; valosin-containing protein

Many neurodegenerative diseases are thought to be caused by a buildup of toxic proteins in the brain from or resulting in promotion of apoptosis. p97 AAA ATPase (also known as VCP, CDC48, TER ATPase) functions in multiple biological processes, targeting proteins to 2 major degradation systems, the proteasome and autophagy machinery. The key role of p97 in proteasome and autophagy degradations underscores its importance and supports involvement of p97 dysregulation in protein misfolding, aggregation, and processing errors, eventually resulting in cell death. Single amino acid mutations in p97/VCP cause autosomal dominant human disorders including hereditary frontotemporal dementia hereditary (FTD) and a specific condition called inclusion body myopathy with Paget disease of the bone plus ALS, a motor neuron disease also known as Lou Gehrig's disease. Mutation sources could be genetic, environmental, spontaneous, or age related. The goal of this project is to identify key pathogenic mechanisms that will be used to develop precision therapy to correct the defect due to p97 disease mutations, without damaging normal p97 functions. Our central hypothesis: p97 disease mutants have abnormal conformation, which in turn leads to altered protein interactome that in specific cells including neuronal cells cause pathogenic effect To test this hypothesis and to identify key pathogenic mechanisms that can act as targets for therapeutic intervention, we propose to compare the interactome of WT and disease mutants of p97 in neuronal and muscle cells derived from patient fibroblasts and then use genetic and biochemical approaches to determine the effect of the altered interactors in regulating p97 ATPase activity and in modulating the disease phenotype. Overall, a new paradigm of how to develop mutant-targeted therapeutics for neurodegenerative diseases—especially for causative mutants in the ATPase protein family— will be established.

许多神经退行性疾病被认为是由大脑中有毒蛋白质的积累引起的